Fate Therapeutics, Inc.
FATEDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
4wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
Conference — FT819
For Systemic Sclerosis. Fate Therapeutics announced that preliminary clinical data for FT819, an off-the-shelf CAR T-cell product candidate for systemic sclerosis, will be presented at the ISSCR 2026 Annual Meeting in Montréal on July 8-11, 2026.
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How FATE's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ProTmune | Phase 2 | Hematologic Malignancies | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Fate Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Fate Therapeutics, Inc.'s (FATE) pipeline across Phase 2. Its lead program is ProTmune (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Fate Therapeutics, Inc.'s next FDA catalyst?→
Fate Therapeutics, Inc.'s (FATE) next tracked catalyst is a Conference expected July 8, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track FATE biotech catalysts?→
Add FATE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Fate Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.